Category - Markets

Markets

Echelon starts Valeo Pharma at speculative buy; PT $1 (Canadian)

Echelon Capital Markets initiated coverage of Valeo Pharma (TSX:VPH) with a “speculative buy” rating and price target of $1 (Canadian). The stock closed at 55 cents on March 8. Valeo commercializes de-risked, innovative...

March 9, 2023

Markets

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...

March 8, 2023

Markets

Stifel starts Mineralys at buy; PT $45

Stifel launched coverage of Mineralys Therapeutics (NASDAQ:MLYS) with a “buy” rating and 12-month price target of $45. The stock closed at $18.96 on March 7. Mineralys’ lorundrostat is targeting hyperaldosteronism, a...

March 7, 2023

Markets

SVB starts Structure Therapeutics at OP; PT $33

SVB Securities initiated coverage of Structure Therapeutics (NASDAQ:GPCR) with an “outperform” rating and $33 price target. The stock closed at $24 on Feb. 27. “Our investment thesis is that the company’s platform and...

February 28, 2023

Markets

SVB starts Disc Medicine at OP; PT $36

SVB Securities launched coverage of Disc Medicine (NASDAQ:IRON) with an “outperform” rating and $36 price target. The stock closed at $24.39 on Feb. 27. Disc Medicine is a clinical-stage biopharmaceutical company...

February 28, 2023

Markets

Piper starts Orchestra Biomed at OW; PT $15

Piper Sandler launched coverage of Orchestra Biomed (NASDAQ:OBIO) with an “overweight” rating and $15 price target. The stock closed at $10.30 on Feb. 23. The company develops solutions in cardiac neuromodulation and...

February 24, 2023

Markets

Research Capital sees Theralase’s Ruvidar NMIBC as potentially better than Keytruda

Research Capital likes the potential chances of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar photodynamic therapy being better than Merck’s Keytruda for treating Bacillus Calmette-Guérin (BCG)-unresponsive...

February 23, 2023

Markets

Dawson James starts Hillstream at buy; PT $4

Dawson James Securities initiated coverage of Hillstream BioPharma (NASDAQ:HILS) with a “buy” rating and price target of $4. The stock closed at $1.24 on Feb. 21. Hillstream is a preclinical biotechnology company...

February 22, 2023

Markets

AGP starts CollPlant at buy; PT $22.75

Alliance Global Partners initiated coverage of CollPlant Biotechnologies (NASDAQ:CLGN) with a “buy” rating and price target of $22.75. The stock closed at $11.80 on Feb. 16. CollPlant has developed a proprietary method...

February 17, 2023

Markets

Cantor starts Transgene at OW; PT €4

Cantor Fitzgerald launch coverage of France-based Transgene (TNG:PA) with an “overweight” rating and a 12-month price target of €4. The stock was quoted at €2.01 on Feb. 17. “Our constructive view on Transgene stock is...

February 17, 2023

Category - Markets

Echelon starts Valeo Pharma at speculative buy; PT $1 (Canadian)

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Stifel starts Mineralys at buy; PT $45

SVB starts Structure Therapeutics at OP; PT $33

SVB starts Disc Medicine at OP; PT $36

Piper starts Orchestra Biomed at OW; PT $15

Research Capital sees Theralase’s Ruvidar NMIBC as potentially better than Keytruda

Dawson James starts Hillstream at buy; PT $4

AGP starts CollPlant at buy; PT $22.75

Cantor starts Transgene at OW; PT €4

General

More